article Open AccessTop 1% cited

Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes

New England Journal of Medicine · 2007 · Vol. 357(20) · pp. 2001–2015

Stephen D. Wiviott✉(Harvard University)Eugene Braunwald(Brigham and Women's Hospital)Carolyn H. McCabe(Harvard University)Gilles Montalescot(Inserm)Witold Rużyłło(Institute of Cardiology)Shmuel Gottlieb(Bikur Cholim Hospital)F.-J. Neumann(Universitäts-Herzzentrum Freiburg-Bad Krozingen)Diego Ardissino(Ospedale di Parma)Stefano De Servi(Azienda Ospedaliera Ospedale Civile di Legnano)Sabina A. Murphy(Harvard University)Jeffrey Riesmeyer(Eli Lilly (United States))Govinda J. Weerakkody(Eli Lilly (United States))C. Michael Gibson(Harvard University)Elliott M. Antman(Harvard University)

View via DOI Full-text PDF

Abstract

In patients with acute coronary syndromes with scheduled percutaneous coronary intervention, prasugrel therapy was associated with significantly reduced rates of ischemic events, including stent thrombosis, but with an increased risk of major bleeding, including fatal bleeding. Overall mortality did not differ significantly between treatment groups. (ClinicalTrials.gov number, NCT00097591 [ClinicalTrials.gov].)

Antiplatelet Therapy and Cardiovascular Diseases Acute Myocardial Infarction Research Venous Thromboembolism Diagnosis and ManagementPrasugrelMedicineClopidogrelAcute coronary syndromeCardiologyInternal medicineAspirinMyocardial infarction

MeSH terms

Prasugrel HydrochlorideClopidogrelAgedAspirinDouble-Blind MethodDrug Therapy, CombinationFemaleHemorrhageHumansMaleMiddle AgedMyocardial InfarctionPiperazinesPlatelet Aggregation InhibitorsProdrugs

Citations

6,705

FWCI

204.45

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation